Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : TEVJF save search
Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals
Published: 2022-09-08 (Crawled : 13:20) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 15.18%
H: 4.65%
C: 3.18%
trials global
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data at EADV 2022 showed significant improvements in signs and symptoms of prurigo nodularis
Published: 2022-09-08 (Crawled : 16:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 15.18%
H: 4.65%
C: 3.18%
dupixent
Dupixent® (dupilumab) Late-breaking Phase 3 Data at the EADV 2022 Congress Showed Significant Improvements in Signs and Symptoms of Prurigo Nodularis
Published: 2022-09-08 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 15.18%
H: 4.65%
C: 3.18%
dupixent
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
Published: 2024-02-26 (Crawled : 10:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: 11.35%
H: 0.84%
C: -3.25%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: 0.0%
H: 1.6%
C: -0.49%
million
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
Published: 2024-01-19 (Crawled : 17:00) - globenewswire.com
ALVO | $12.9 0.78% 0.78% 90K
|
n/a
|
| O: 6.64%
H: 11.54%
C: 8.1%
KMDA | $5.075 -0.1% -0.1% 6.5K
|
Health Technology
|
| O: -0.85%
H: 1.46%
C: 0.69%
avt02 avt04 license update
Oramed Pharmaceuticals Appoints Chief Legal Officer
Published: 2021-12-08 (Crawled : 13:30) - biospace.com/
ORMP | $2.19 -6.01% -6.39% 240K
|
Health Technology
|
| O: 5.82%
H: 3.16%
C: 0.82%
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
Published: 2024-02-08 (Crawled : 13:00) - globenewswire.com
ACRV P | $10.56 2.13% 2.08% 370K
|
|
| O: 5.75%
H: 0.0%
C: -8.29%
VIGL | $2.75 -5.82% -6.18% 50K
|
|
| O: 1.05%
H: 1.52%
C: -1.39%
therapeutics
Teva Reports Second Quarter 2023 Financial Results
Published: 2023-08-02 (Crawled : 15:00) - biospace.com/
TEVA | $12.78 -3.03% -0.24% 9M
|
Health Technology
|
| O: 5.55%
H: 8.46%
C: 5.71%
teva financial results
Teva to Present Latest Research From Neurology Portfolio at the 2022 American Psychiatric Association Annual Meeting
Published: 2022-05-17 (Crawled : 12:20) - biospace.com/
TEVA | $12.78 -3.03% -0.24% 9M
|
Health Technology
|
| O: 4.77%
H: 4.8%
C: 3.32%
research
Teva Announces New Findings Highlighting Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder to Address Asthma Treatment Challenges
Published: 2022-05-17 (Crawled : 12:20) - biospace.com/
TEVA | $12.78 -3.03% -0.24% 9M
|
Health Technology
|
| O: 4.77%
H: 4.8%
C: 3.32%
proair treatment potential
Regeneron Reports Second Quarter 2022 Financial and Operating Results
Published: 2022-08-03 (Crawled : 11:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 4.36%
H: 3.91%
C: 1.46%
results
Novel Costimulatory Bispecific Antibody Shows Encouraging Anti-tumor Activity When Combined with PD-1 Inhibitor Libtayo® (cemiplimab) in Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
Published: 2022-08-03 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: -2.6%
H: 0.0%
C: -0.76%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.17%
H: 0.12%
C: -1.29%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 4.36%
H: 3.91%
C: 1.46%
libtayo antibody cancer prostate cancer pd-1 inhibitor
Breast Cancer Therapeutics Market 2023, USD 15.64 billion Growth is Expected between 2023 to 2028, Robust pipeline and new drug approvals to Boost Growth - Technavio
Published: 2024-01-30 (Crawled : 18:00) - prnewswire.com
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 5.68%
H: 0.77%
C: 0.77%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 3.41%
H: 0.0%
C: -2.45%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.08%
H: 3.47%
C: -0.25%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -2.04%
H: 0.19%
C: -1.97%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 4.04%
H: 1.57%
C: -3.02%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.5%
H: 0.07%
C: -0.81%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.75%
H: 0.0%
C: 0.0%
PBYI | $4.98 -3.68% -3.82% 290K
|
Health Technology
|
| O: -0.1%
H: 2.31%
C: -1.26%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.82%
H: 0.12%
C: -1.64%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.44%
H: 0.2%
C: -0.55%
drug breast expected cancer pipeline therapeutics growth market
Topical Corticosteroids Market to Grow by USD 1.08 billion between 2022 to 2027, globally at 4% CAGR - Technavio
Published: 2024-01-30 (Crawled : 23:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K
|
Health Technology
|
| O: 4.34%
H: 0.0%
C: 0.0%
GLAXF | $20.2 -14.18% 510
|
Health Technology
|
| O: 5.68%
H: 0.77%
C: 0.77%
AZNCF | $140.15 -4.19% 560
|
Health Technology
|
| O: 3.41%
H: 0.0%
C: -2.45%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 0.0%
H: 1.38%
C: 0.26%
VTRS | $11.11 0.09% 0.09% 3.5M
|
Health Technology
|
| O: -0.08%
H: 3.47%
C: -0.25%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -2.04%
H: 0.19%
C: -1.97%
GSK | $39.27 -0.83% 0.01% 2.2M
|
Health Technology
|
| O: 4.04%
H: 1.57%
C: -3.02%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.5%
H: 0.07%
C: -0.81%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 1.75%
H: 0.0%
C: 0.0%
AZN | $68.36 -0.25% -0.25% 4M
|
Health Technology
|
| O: 0.82%
H: 0.12%
C: -1.64%
market
Teva Launches New “Pivot to Growth” Strategy
Published: 2023-05-18 (Crawled : 13:20) - biospace.com/
TEVA | $12.78 -3.03% -0.24% 9M
|
Health Technology
|
| O: 3.94%
H: 3.67%
C: -2.25%
teva
New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19
Published: 2021-11-08 (Crawled : 12:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 1.4K
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K
|
Health Technology
|
| O: 3.88%
H: 0.78%
C: 0.68%
covid casirivimab phase 3
Teva Reports Fourth Quarter and Full Year 2021 Financial Results
Published: 2022-02-09 (Crawled : 13:30) - biospace.com/
EGRX | $4.505 2.62% 2.55% 140K
|
Health Technology
|
| O: 3.87%
H: 1.76%
C: 0.69%
financial results report results
Lymphoma Treatment Global Market to Reach $18.5 Billion by 2027 at a CAGR of 8.89%
Published: 2022-11-10 (Crawled : 13:00) - prnewswire.com
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: 2.34%
H: 2.51%
C: 2.29%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 1.09%
H: 0.48%
C: 0.4%
BMY | $48.3 0.96% -0.1% 11M
|
Health Technology
|
| O: 1.22%
H: 0.01%
C: -1.7%
ABT | News | $105.27 -0.6% -0.15% 7.3M
|
Health Technology
|
| O: 3.59%
H: 1.37%
C: 1.16%
treatment global market
Global Genitourinary Drugs Market Research Report to 2027 - Increasing Prevalence of Genitourinary Disorders is Driving Growth
Published: 2022-04-26 (Crawled : 14:00) - prnewswire.com
ALPMF | $9.594 43.47% 2.2K
|
Health Technology
|
| O: 2.56%
H: 0.0%
C: 0.0%
ALPMY | $9.46 -1.11% 500K
|
Manufacturing
|
| O: 0.13%
H: 0.06%
C: -0.69%
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 3.08%
H: 0.0%
C: 0.0%
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.47%
H: 0.83%
C: -1.44%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: 2.0%
H: 0.0%
C: 0.0%
LLY | $745.95 -0.64% -0.1% 1.7M
|
Health Technology
|
| O: 0.34%
H: 1.41%
C: -1.17%
IONS | $40.81 -0.24% -0.25% 990K
|
Health Technology
|
| O: -0.12%
H: 0.07%
C: -5.13%
research report growth market drug
Retinal drugs market size to increase by USD 7.27579 billion; North America to account for 42% of market growth - Technavio
Published: 2023-02-08 (Crawled : 12:20) - prnewswire.com
NVS | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: 0.72%
H: 0.52%
C: -0.08%
ALC | $78.47 -0.67% -0.01% 760K
|
Health Technology
|
| O: 0.28%
H: 0.21%
C: -0.41%
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.19%
H: 0.65%
C: -0.55%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 3.05%
H: 0.0%
C: 0.0%
MGTX | News | $5.02 -4.38% -4.58% 240K
|
Health Technology
|
| O: -1.14%
H: 4.62%
C: -0.77%
america growth market
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.